2014’s Top Biopharma Dealmakers
Executive Summary
Big Pharmas exchanging assets featured in 2014 M&As. Cancer alliances represented the largest group of partnerships, and J&J was again the most active in-licenser.
You may also be interested in...
Biopharma In 2014: Early Access Gains Offset Taxation, Pricing Woes
The year was marked by record levels of biopharma M&A activity and a strong IPO market. Measures designed to deliver early access to new medicines continued to advance on both sides of the Atlantic, while pricing came in for renewed attention as new, highly effective but extremely expensive products reached the market.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.